|
Greetings! |
Scleroderma Foundation Awarded Charity Navigator's Highest Rating
For the fourth year in a row, Charity Navigator, the independent organization that rates the financial health and efficiency of charities, gave its top rating of four stars to the Scleroderma Foundation. This "exceptional" rating indicates that the Scleroderma Foundation "consistently executes its mission in a fiscally responsible way, and outperforms most other charities in America." Charity Navigator's rating system examines two broad areas of a charity's financial health: 1) how responsibly it functions day to day and 2) how well positioned it is to sustain its programs over time. According to Charity Navigator, this four-star designation reflects the commitment of the Scleroderma Foundation's leadership to strengthening its overall operation, effectiveness and cost reduction practices.
|
|
Are you interested in learning about how work will affect your Social Security benefits? |
If you are interested in learning about the Ticket to Work Program or Work Incentives, you can attend a free Work Incentive Seminar Event (WISE) online webinar.
WISE webinars are online events held for beneficiaries to learn about the Ticket to Work Program and available Work Incentives through accessible learning opportunities. WISE webinars are hosted on the fourth Wednesday of each month.
To attend an online WISE webinar, visit https://www.chooseworkttw.net/wise/jsp/wise.jsp |
|
Chronic Kidney Disease and Nutrition |
The purpose of medical nutrition therapy (MNT) for chronic kidney disease (CKD) is to maintain good nutritional status, slow progression, and to treat complications.
The key diet components to slowing progression of CKD are:
- Controlling blood pressure by reducing sodium intake
- Reducing protein intake, if excessive
- Managing diabetes
To learn more about CKD and nutrition and to access educational materials, visit nkdep.nih.gov |
|
Stem Cell Transplant Boosts Survival in Scleroderma |
BERLIN - Hematopoietic stem cell transplantation appears to be a breakthrough in the treatment of poor-prognosis early diffuse cutaneous systemic sclerosis.
This complex, multistage therapy produced significantly better long-term survival than conventional pulsed-dose cyclophosphamide, despite the 10% treatment-related mortality in the first 100 days, according to the first report from the ASTIS (Autologous Stem Cell Transplantation International Scleroderma) trial.
|
|
Disclaimer: The Scleroderma Foundation in no way endorses any drugs or treatments reported in the eLetter. Information is provided to keep readers informed. Because the manifestations and severity of scleroderma vary among individuals, personal medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader's physician(s) for proper evaluation and treatment.
|
|
|
|
